Lactoferrin-Modified Ultra-Sustained Release Propofol Nanoparticles for Multi-Pathway Therapy of Depression via Intraperitoneal Injection
International Journal of Nanomedicine · 2026
DOI: 10.2147/ijn.s645818 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von Zhenyi Wu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Center for Brain Science, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic …. Hauptthemen laut MEDLINE: Propofol, Depression, Nanoparticles, Lactoferrin. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Depression
Abstract (Originalsprache)
Background
Depression imposes a significant burden on global public health, and traditional antidepressants are limited by slow onset, low efficacy, and high recurrence rates. Intraperitoneal injection of propofol can rapidly exert anti-anhedonic effects by regulating the VTA-NAc dopaminergic and GABAergic signaling pathways. However, its application in depression treatment is limited by rapid systemic clearance, poor brain permeability, and significant systemic toxicity. Moreover, the simple lipophilic structure of propofol and the limited drug-loading and long-term controlled-release performance of conventional physically encapsulated nanocarriers hinder the development of long-acting propofol formulations.
Methods
Lactoferrin-functionalized PVA-propofol nanoparticles (LF-PVA@Pro NPs) were prepared based on the strong intermolecular affinity between PVA and propofol, as validated by molecular dynamics simulations. Their physicochemical properties, in vitro release behavior, brain-targeting efficiency, biosafety, and in vivo antidepressant efficacy were systematically characterized using CRS-induced depressive mouse models through multiple behavioral and histological assessments.
Results
LF-PVA@Pro NPs achieved a drug loading of 19.3% and exhibited sustained in vitro release for 100 h. Following intraperitoneal injection, the formulation maintained therapeutic brain concentrations for 100 h (6-8-fold longer than free propofol) and increased cerebral drug accumulation by 2.5-fold. Its LD50 was 2802 mg/kg, 2.36-fold higher than that of free propofol, ensuring safety at the therapeutic dose of 40 mg/kg. In vivo studies demonstrated that LF-PVA@Pro NPs markedly alleviated depressive- and anxiety-like phenotypes, reduced VTA/NAc neuronal injury, and restored c-Fos, GABA, and DAT expression, thereby reactivating reward circuits.
Conclusion
LF-modified ultra-sustained brain-targeted nanoparticles enable multi-pathway long-term depression intervention, offering a translatable strategy to repurpose propofol as a rapid-onset antidepressant for chronic stress-related depression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Center for Brain Science, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
- Yan'an Medical College of Yan'an University, Yan'an, Shaanxi, People's Republic of China.
- Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, People's Republic of China.
- Center for Translational Medicine, The First Affiliated Hospital of Xi' an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
- College of Forensic Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
- Key Laboratory of Biomedical Information Engineering of the Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
ORCID-Profile: Lu Yu, Yufeng Xun, Xiancang Ma, Daocheng Wu
Zitieren
APA
Wu, Z., Deng, J., Li, S., Yu, L., Zhang, H., Xun, Y., Bian, J., Liu, J., Zhang, J., Lei, P., Ma, Q., Fan, Y., Yang, Z., Zhu, F., Ma, X., Wu, D., & Zhang, S. (2026). Lactoferrin-Modified Ultra-Sustained Release Propofol Nanoparticles for Multi-Pathway Therapy of Depression via Intraperitoneal Injection. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s645818
Vancouver
Wu Z, Deng J, Li S, Yu L, Zhang H, Xun Y, et al. Lactoferrin-Modified Ultra-Sustained Release Propofol Nanoparticles for Multi-Pathway Therapy of Depression via Intraperitoneal Injection. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s645818
BibTeX
@article{Wu2026,
author = {Wu, Zhenyi and Deng, Junze and Li, Shunlian and Yu, Lu and Zhang, Hang and Xun, Yufeng and Bian, Jing and Liu, Jing and Zhang, Jianbo and Lei, Pu and Ma, Qingyan and Fan, Yajuan and Yang, Zai and Zhu, Feng and Ma, Xiancang and Wu, Daocheng and Zhang, Shuo},
title = {Lactoferrin-Modified Ultra-Sustained Release Propofol Nanoparticles for Multi-Pathway Therapy of Depression via Intraperitoneal Injection},
journal = {International Journal of Nanomedicine},
year = {2026},
doi = {10.2147/ijn.s645818}
}
EUVIMED